Yu Fujiwara: ASCO Breakthrough to Highlight Advances in Esophageal, Nasopharyngeal, Lung Cancers

Yu Fujiwara, Hematology/Oncology Fellow at Roswell Park Comprehensive Cancer Center, shared on X:

” ‘ASCO Breakthrough to Highlight Advances in Esophageal, Nasopharyngeal, Lung Cancers.’

Abstract 142 – IMRT vs CCRT for low risk nasopharyngeal ca, p3, OL, non-inferior trial, from China.

Really great to see a comparable result, supporting a de-escalation strategy for low risk nasopharyngeal ca.

With a median follow-up of 70.1 months, the IMRT-alone group had a similar 5-year overall survival (95.2% vs. 98.2%, hazard ratio, 2.27 [95%CI:0.70-7.40]; P=0.16), failure-free survival (86.2% vs. 88.4%, hazard ratio, 1.16 [95%CI:0.64-2.07]; p = 0.63).”

Read further.
Source: Yu Fujiwara/X